For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230712:nRSL8190Fa&default-theme=true
RNS Number : 8190F ReNeuron Group plc 12 July 2023
ReNeuron Group plc
("ReNeuron" or the "Company")
Share Purchase by Chief Financial Officer
ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived exosome
technologies, announces that John Hawkins, CFO of the Company, has today
purchased 52,332 of the Company's ordinary shares of 1p each ("Ordinary
Shares").
Name Title Number of Ordinary Shares purchased Resulting beneficial interest in the Company's Ordinary Shares Percentage of Company's Total Voting Rights
John Hawkins Chief Financial Officer 52,332 200,000 0.35%
ENDS
Enquiries:
ReNeuron www.reneuron.com/investors (http://www.reneuron.com/investors)
Iain Ross, Executive Chairman Via Walbrook PR
John Hawkins, Chief Financial Officer
Allenby Capital Limited (Nominated Adviser and Broker) +44 (0)20 3328 5656
James Reeve/George Payne/Dan Dearden-Williams (Corporate Finance)
Stefano Aquilino (Sales & Corporate Broking)
Walbrook PR (Media & Investor Relations) +44 (0)20 7933 8780 or reneuron@walbrookpr.com
(mailto:reneuron@walbrookpr.com)
Paul McManus / Alice Woodings +44 (0)7980 541 893 / +44 (0)7407 804 654
About ReNeuron
ReNeuron has developed a proprietary stem cell-derived, exosome-based, drug
delivery platform with customisable cellular targeting capabilities for the
delivery of complex drug modalities.
Through the generation of several unique and scalable exosome producer cell
lines, our CustomEX™ platform can be optimised for specific tissues targets
and payloads leading to improvements in therapeutic outcome and a reduction in
off-target effects. ReNeuron offers a delivery mechanism for a variety of
payloads such as siRNA, mRNA, proteins, small molecules and genes. Through its
conditionally immortalised induced pluripotent stem cell (iPSC) platform, the
Company can make allogeneic tissue cells of choice and has the potential to
produce exosomes with tissue specific targeting ability.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.
For further information visit www.reneuron.com (http://www.reneuron.com/)
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
(Disclosure in relation to ordinary shares purchased by Directors and PDMRs)
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name John Hawkins
2 Reason for the notification
a) Position/status Chief Financial Officer
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name ReNeuron Group plc
b) LEI 2138003TU12CQ5TZO137
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares 1 pence
Identification code RENE - GB00BF5G6K95
b) Nature of the transaction Acquisition of ordinary shares
c) Price(s) and volume(s) Price(s) (pence) Volume(s)
8.949p 52,332
d) Aggregated information 52,332 ordinary shares at an average price of GBP 0.08949 at a total value of
£4,683.19
e) Date of the transaction 12 July 2023
f) Place of the transaction London Stock Exchange AIM Market
d)
Aggregated information
52,332 ordinary shares at an average price of GBP 0.08949 at a total value of
£4,683.19
e)
Date of the transaction
12 July 2023
f)
Place of the transaction
London Stock Exchange AIM Market
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHEAEXAFSDDEFA